剪切波弹性成像在评估自身免疫性肝炎患者肝纤维化和治疗反应中的作用

肝脏 ›› 2023, Vol. 28 ›› Issue (7): 772-774.

剪切波弹性成像在评估自身免疫性肝炎患者肝纤维化和治疗反应中的作用

施霞, 倪雪君, 马鑫, 武豆, 黄晨

226007 江苏南通大学医学院(施霞,黄晨);201508 上海市公共卫生临床中心超声科(施霞,马鑫,武豆);226006 南通大学附属医院超声科(倪雪君),血管外科(黄晨)

收稿日期:2023-03-04 发布日期:2023-09-19
通讯作者: 黄晨, Email:huangchen132@sina.com
基金资助:
上海市公共卫生临床中心科研基金(KY-GW-2020-25)

The role of shear wave elastography in evaluating hepatic fibrosis and therapeutic response in patients with autoimmune hepatitis

SHI Xia^1,2, NI Xue-jun³, MA Xin², WU Dou², HUANG Chen^1,4

1. Medical School of Nantong University Nantong City, Jiangsu Province 226007;
2. Department of Ultrasound Medicine, shanghai Public Health Clinical Center, Fudan University Shanghai 201508;
3. Department of Ultrasound Medicine, Nantong University Affiliated Hospital Nantong City, Jiangsu Province 226006;
4. Department of Vascular surgery, Nantong University Affiliated Hospital Nantong City, Jiangsu Province 226006

Received:2023-03-04 Published:2023-09-19
Contact: HUANG Chen, Email:huangchen132@sina.com

摘要/Abstract

摘要： 目的确定剪切波弹性成像(SWE)在评估自身免疫性肝炎(AIH)患者的肝脏硬度值(LSM)和治疗反应中的有效性。方法收集2017年6月至2022年10月期间入院诊治的AIH患者65例。根据METAVIR分类对AIH肝纤维化状态进行分期。对AIH患者进行标准化治疗,其中类固醇治疗为泼尼松联合或不联合硫唑嘌呤。比较治疗前后不同肝纤维化分期AIH临床资料,采用受试者工作特征(ROC)曲线分析LSM对AIH肝纤维化分期的预测价值。结果 65例AIH患者中F1、F2、F3及F4期分别为16例、21例、15例及13例。F1期AIH患者PLT、Alb为238(193,420)×10⁹/L、41.2(38.0,43.3)g/L,F2期为194(130,253)×10⁹/L、37.4(36.2,40.4)g/L、F3期为167(92,233)×10⁹/L、37.0(35.1,39.0)g/L、F4期为118(74,170)×10⁹/L、34.4(32.2,37.1)g/L,差异有统计学意义(P<0.05)。F1期AIH患者APRI、FIB-4及LSM为2.6(1.7,4.1)、3.0(2.0,4.5)、7.2(5.0,9.7)kPa,F2期为4.4(2.8,6.8)、6.4(3.4,8.3)及12.7(7.7,15.3)kPa、F3期为5.7(3.0,7.2)、9.3(5.8,13.2)、13.0(9.2,18.7)kPa、F4期为2.3(1.4,3.8)、8.7(6.4,12.9)、15.4(13.3,21.5)kPa,差异有统计学意义(P<0.05)。LSM对≥F2期AIH肝纤维化诊断截断点、AUC分别为8.7 kPa、0.90(0.81~0.96);对F4期AIH肝纤维化诊断截断点、AUC分别为13.6 kPa、0.85(0.75~0.93),高于APRI、FIB-4(P<0.05)。65例AIH患者中接受、未接受类固醇治疗分别为43例、22例。与基线时比,接受、未接受类固醇治疗AIH患者随访时ALT、AST均显著降低(P<0.05);与基线时[4.7(3.4,7.2)、8.2(6.5,13.2)及13.3(9.7,21.5)kPa]比,接受类固醇治疗AIH患者随访时APRI、FIB-4及LSM均显著下降[0.6(0.4,0.8)、3.3(1.4,4.9)及7.5(3.2,9.4)kPa,P<0.05],而未接受类固醇治疗AIH患者基线、随访时APRI、FIB-4及LSM差异无统计学意义(P>0.05)。结论 SWE是评估AIH患者肝纤维化的有效方法。在随访过程中LSM可作为评估AIH治疗反应的参数。

关键词: 自身免疫性肝炎, 剪切波弹性成像, 肝脏硬度值, 泼尼松, 受试者工作特征曲线

Abstract: Objective To determine the effectiveness of shear wave elastography (SWE) in evaluating liver stiffness measurement (LSM) to assess liver fibrosis and treatment response in patients with autoimmune hepatitis (AIH). Methods A total of 65 patients with AIH between June 2017 and October 2022 were enrolled, including 7 males and 58 females, averagely aged 57 (41, 73) years. The diagnosis of AIH met the requirements. According to METAVIR classification, AIH liver fibrosis was classified into stages. Standardized treatment was prednisone combined with or without azathioprine. The clinical data of AIH before and after treatment was compared, and the predictive value of LSM for AIH liver fibrosis staging was analyzed using the ROC curve. Results Among the 65 patients with AIH, there were 16 cases in F1, 21 cases in F2, 15 cases in F3 and 13 cases in F4 stages, respectively. The PLT and Alb of patients with stage F1 AIH were 238 (193, 420) ×10⁹/L and 41.2 (38.0, 43.3) g/L, compared with F2 [194 (130, 253) ×10⁹/L, 37.4 (36.2, 40.4) g/L], F3 [167 (92, 233) ×10⁹/L, 37.0 (35.1, 39.0) g/L] and F4 [118 (74, 170) ×10⁹/L, 34.4 (32.2, 37.1) g/L], F3 [167 (92, 233) ×10⁹/L, 37.0 (35.1, 39.0) g/L], with statistically significant difference (P<0.05). The APRI, FIB-4 and LSM of patients with F1 AIH were 2.6 (1.7, 4.1), 3.0 (2.0, 4.5) and 7.2 (5.0, 9.7) kPa, compared with F2 [4.4 (2.8, 6.8), 6.4 (3.4, 8.3) and 12.7 (7.7, 15.3) kPa], F3 [5.7 (3.0, 7.2), 9.3 (5.8, 13.2) and 13.0 (9.2, 18.7) kPa] and F4 [2.3 (1.4, 3.8), 8.7 (6.4, 12.9) and 15.4 (13.3, 21.5) kPa], with statistically significant difference was (P<0.05). The AUC value of LSM in diagnosis of hepatic fibrosis of AIH in stage ≥F2 and F4 was significantly higher than that of APRI and FIB-4(P<0.05). The cut-off point and AUC value of LSM in diagnosis of AIH liver fibrosis in stage ≥F2 were 8.7 kPa and 0.90 (0.81-0.96), respectively. The cut-off point and AUC value of diagnosis of liver fibrosis in F4 AIH were 13.6kPa and 0.85(0.75-0.93), respectively. Among 65 patients with AIH, 43 patients received steroid therapy and 22 patients did not. Compared with the baseline, both the steroid group and non-steroid group showed significant decreases in ALT and AST during follow-up (P<0.05). Furthermore, the steroid group showed significant decreases in APRI, FIB-4 and LSM [0.6 (0.4, 0.8), 3.3 (1.4, 4.9) and 7.5 (3.2, 9.4) kPa, P<0.05]. However, there was no significant difference in APRI, FIB-4 and LSM at baseline and follow-up in non-steroid group (P>0.05). Conclusion SWE is an effective method to evaluate liver fibrosis in AIH patients. LSM can be used as a reliable parameter to evaluate the response of AIH upon the treatments.

Key words: Autoimmune hepatitis, Shear wave elastography, Liver stiffness measurement, Prednisone, Receiver operating characteristic curve

施霞, 倪雪君, 马鑫, 武豆, 黄晨. 剪切波弹性成像在评估自身免疫性肝炎患者肝纤维化和治疗反应中的作用[J]. 肝脏, 2023, 28(7): 772-774.

SHI Xia, NI Xue-jun, MA Xin, WU Dou, HUANG Chen. The role of shear wave elastography in evaluating hepatic fibrosis and therapeutic response in patients with autoimmune hepatitis[J]. Chinese Hepatolgy, 2023, 28(7): 772-774.

参考文献

[1] Mack CL, Adams D, Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American association for the study of liver diseases. Hepatology, 2020, 72(2):671-722.
[2] Alvarez F, Berg PA, Bianchi FB, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol, 1999, 31(5):929-938.
[3] Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology, 2010, 51(6):2193-2213.
[4] Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol, 2004, 40:646-652.
[5] Sebastiani G. Non-invasive assessment of liver fibrosis in chronic liver diseases: implementation in clinical practice and decisional algorithms. World J Gastroenterol, 2009, 15:2190-2203.
[6] Friedman SL. Liver fibrosis: from bench to bedside. J Hepatol, 2003, 38 Suppl 1:S38-S53.
[7] Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med, 2001, 344:495-500.
[8] Chin JL, Pavlides M, Moolla A, et al. Non-invasive markers of liver fibrosis: adjuncts or alternatives to liver biopsy Front Pharmacol, 2016, 7:159.
[9] Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology, 1996, 24:289-293.
[10] 中华医学会肝病学分会. 自身免疫性肝炎诊断和治疗指南(2021). 中华肝脏病杂志, 2022, 30(5):482-492.
[11] Xu Q, Sheng L, Bao H, et al. Evaluation of transient elastography in assessing liver fibrosis in patients with autoimmune hepatitis. J Gastroenterol Hepatol, 2017, 32:639-644.
[12] Wu S, Yang Z, Zhou J, et al. Systematic review: diagnostic accuracy of non-invasive tests for staging liver fibrosis in autoimmune hepatitis. Hepatol Int, 2019, 13:91-101.
[13] Xing X, Yan Y, Shen Y, et al. Liver fibrosis with two-dimensional shear-wave elastography in patients with autoimmune hepatitis. Expert Rev Gastroenterol Hepatol, 2020, 14:631-638.
[14] Yada N, Sakurai T, Minami T, et al. Influence of liver inflammation on liver stiffness measurement in patients with autoimmune hepatitis evaluation by combinational elastography. Oncology, 2017, 92 Suppl 1:10-15.
[15] Ferraioli G, Maiocchi L, Dellafiore C, et al. Performance and cutoffs for liver fibrosis staging of a two-dimensional shear wave elastography technique. Eur J Gastroenterol Hepatol, 2021, 33:89-95.